4//SEC Filing
Onconova Therapeutics, Inc. 4
Accession 0001179110-13-012445
$TRAWCIK 0001130598operating
Filed
Jul 31, 8:00 PM ET
Accepted
Aug 1, 4:13 PM ET
Size
50.2 KB
Accession
0001179110-13-012445
Insider Transaction Report
Form 4
MEHTA VIREN
Director
Transactions
- Conversion
Common Stock
2013-07-30+73,839→ 85,479 total - Purchase
Common Stock
2013-07-30$15.00/sh+16,667$250,005→ 126,914 total - Conversion
Common Stock
2013-07-30+6,768→ 6,768 total(indirect: By Foundation) - Conversion
Common Stock
2013-07-30+755→ 8,295 total(indirect: By Foundation) - Conversion
Common Stock
2013-07-30+1,722→ 8,056 total(indirect: By LLC) - Conversion
Series B Convertible Preferred Stock
2013-07-30−8,020→ 0 total(indirect: By Foundation)→ Common Stock (6,768 underlying) - Conversion
Series B Convertible Preferred Stock
2013-07-30−1,245→ 0 total(indirect: By LLC)→ Common Stock (1,050 underlying) - Conversion
Common Stock
2013-07-30+7,686→ 93,165 total - Conversion
Common Stock
2013-07-30+345→ 1,395 total(indirect: By LLC) - Conversion
Common Stock
2013-07-30+4,632→ 4,632 total(indirect: By LLC) - Conversion
Common Stock
2013-07-30+1,050→ 1,050 total(indirect: By LLC) - Conversion
Series B Convertible Preferred Stock
2013-07-30−87,470→ 0 total→ Common Stock (73,839 underlying) - Conversion
Common Stock
2013-07-30+17,082→ 110,247 total - Conversion
Common Stock
2013-07-30+1,702→ 6,334 total(indirect: By LLC) - Conversion
Common Stock
2013-07-30+338→ 1,733 total(indirect: By LLC) - Conversion
Series I Convertible Preferred Stock
2013-07-30−22,771→ 0 total→ Common Stock (17,082 underlying) - Conversion
Series D Convertible Preferred Stock
2013-07-30−1,007→ 0 total(indirect: By Foundation)→ Common Stock (755 underlying) - Conversion
Series B Convertible Preferred Stock
2013-07-30−5,488→ 0 total(indirect: By LLC)→ Common Stock (4,632 underlying) - Conversion
Series C Convertible Preferred Stock
2013-07-30−2,270→ 0 total(indirect: By LLC)→ Common Stock (1,702 underlying) - Conversion
Series D Convertible Preferred Stock
2013-07-30−2,296→ 0 total(indirect: By LLC)→ Common Stock (1,722 underlying) - Conversion
Series D Convertible Preferred Stock
2013-07-30−451→ 0 total(indirect: By LLC)→ Common Stock (338 underlying) - Conversion
Common Stock
2013-07-30+772→ 7,540 total(indirect: By Foundation) - Conversion
Series E Convertible Preferred Stock
2013-07-30−10,246→ 0 total→ Common Stock (7,686 underlying) - Conversion
Series C Convertible Preferred Stock
2013-07-30−1,030→ 0 total(indirect: By Foundation)→ Common Stock (772 underlying) - Conversion
Series C Convertible Preferred Stock
2013-07-30−460→ 0 total(indirect: By LLC)→ Common Stock (345 underlying)
Footnotes (12)
- [F1]The Series B Convertible Preferred Stock converted into Common Stock on a 0.85-for-1 basis and had no expiration date.
- [F10]Includes 17,082 shares held jointly with spouse.
- [F11]Includes 13,454 shares held jointly with spouse.
- [F12]Shares held jointly with spouse.
- [F2]Includes 11,356 shares held jointly with spouse.
- [F3]The reporting person is a trustee of the Viram Foundation
- [F4]The reporting person is managing member of Mehta Partners LLC
- [F5]The reporting person is trustee of Mehta Partners LLC FBO Jean Kiss Marie IRA.
- [F6]The Series C Convertible Preferred Stock converted into Common Stock on a 0.75-for-1 basis and had no expiration date.
- [F7]The Series D Convertible Preferred Stock converted into Common Stock on a 0.75-for-1 basis and had no expiration date.
- [F8]The Series E Convertible Preferred Stock converted into Common Stock on a 0.75-for-1 basis and had no expiration date.
- [F9]The Series I Convertible Preferred Stock converted into Common Stock on a 0.75-for-1 basis and had no expiration date.
Documents
Issuer
Onconova Therapeutics, Inc.
CIK 0001130598
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001130598
Filing Metadata
- Form type
- 4
- Filed
- Jul 31, 8:00 PM ET
- Accepted
- Aug 1, 4:13 PM ET
- Size
- 50.2 KB